BIIB News - "Biogen Idec to Present at the Citi 2011 Global Healthcare Conference"
great article Recent SF-1019 Study In no case was there a negative showing as to a safety issue and in most there was a measurable improvement in a clinical condition SF-1019 has shown great promise over a wide range of applications relating to conditions of an inflammatory nature such as Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS).
Following a series of toxicity studies in animals, SF-1019 demonstrated a positive safety profile.
Recently, in one of Argyll Biotechnologies’ pre-clinical human studies, a small number of patients were provided with SF-1019 treatments under informed consent (EU) and a compassionate waiver program (US). Information collected from this study extended over a ten month period and included a brief record of clinical progress (if any), together with dose ranging and toxicity data.
A standard battery of blood tests were undertaken pre-treatment and at four, eight and twelve week intervals. In no case was there a negative showing as to a safety issue and in most there was a measurable improvement in a clinical condition. For example, there were no apparent biochemical changes in the blood analysis and no adverse reactions recorded in this group.
Many of the patients who participated in this program continue to receive compassionate treatments of SF-1019.